Numinus Wellness
Numinus Wellness is a Canadian psychedelic-assisted therapy company operating a vertically integrated platform of clinical services, practitioner training, and clinical trial site operations, supported by a Health Canada-licensed laboratory (Numinus Bioscience) and a training community of over 2,500 practitioners.
- Company typePublic
- Founded2020
- HeadquartersSalt Lake City, United States
- Headcount251–500
- GTM typeB2B and B2C
- OfferingServices
What Numinus Wellness does
Numinus Wellness Inc. is a Canadian mental health company advancing psychedelic-assisted therapy through a vertically integrated platform spanning three business lines: clinical services delivered through a Canadian clinic network (Vancouver, Montreal, Toronto), accredited practitioner training, and clinical trial site operations via Cedar Clinical Research. The company is built around a Health Canada-licensed laboratory, Numinus Bioscience, which holds licenses for psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine for research and production — a regulatory footprint that positioned Numinus as the first publicly traded company in Canada approved to extract and research psilocybin. Service offerings include ketamine-assisted therapy (including Spravato), psilocybin-assisted therapy for treatment-resistant depression, PTSD, and substance use disorders, MDMA-assisted therapy through the MAPS compassionate access trial, and adjunctive modalities such as TMS. The Numinus Care Model — a seven-principle framework covering trauma-informed care, cultural safety, harm reduction, mindfulness, and embodiment — is the codified methodology applied across clinical and training delivery.
On the commercial side, Numinus monetizes through three primary streams: clinical services revenue from patient treatment, professional fees from the board-accredited training platform (Fundamentals of PAT, Applied PAT, Molecular Foundations, Embodied Inquiry, and Psychedelic Harm Reduction & Integration), and laboratory/research services revenue from psychedelic compound production and clinical trial site operations. The practitioner training platform has trained over 2,500 practitioners to date and feeds a Numinus Alumni Network that generates referral flows and continued engagement. Distribution is direct-to-consumer for clinics and self-serve online for training, with no channel partner or reseller model. The company is currently under a cease trade order from the British Columbia Securities Commission, was delisted from the TSX effective April 22, 2026, and has filed an application to list on the Canadian Securities Exchange. Following the 2024 divestiture of US operations (five Utah clinics sold to Stella for US$3.53 million), the company has narrowed its footprint to Canadian clinical and research operations along with its global online training platform, and is pursuing a strategic rebrand to Numinus Intelligence through the MedBright AI acquisition.
Numinus Wellness firmographics
Firmographics- Name
- Numinus Wellness
- Legal name
- Numinus Wellness Inc.
- Website
- https://numinusnetwork.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Numinus Wellness is a Canadian psychedelic-assisted therapy company operating a vertically integrated platform of clinical services, practitioner training, and clinical trial site operations, supported by a Health Canada-licensed laboratory (Numinus Bioscience) and a training community of over 2,500 practitioners.
- Ownership category
- akta.pro rank
Numinus Wellness industry classification
Industry- Product category
- Mental Health Services
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Mental Health Practitioners (except Physicians) (621330)
- SIC
- Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- General Mental Health Therapy Platforms (Talk Therapy) (HLALAEAA)
- akta.pro secondary industry
- Meditation Apps, Digital Courses & Online Communities (HSADAJAH)
Keywords
Where Numinus Wellness is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Numinus Wellness business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Services Revenue: Revenue generated from psychedelic-assisted therapy clinical services delivered through the company's clinic network in Canada (Vancouver, Montreal, Toronto) and through Cedar Clinical Research's trial site operations.
- Practitioner Training Programs: Board-accredited certification pathways and stand-alone courses in psychedelic-assisted therapy, including Fundamentals of PAT, Applied PAT, Molecular Foundations, and Harm Reduction & Integration. Training programs serve both licensed mental health professionals and non-licensed practitioners.
- Laboratory & Research Services: Health Canada licensed laboratory services through Numinus Bioscience, including psychedelic compound production, extraction (including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, ketamine), and manufacturing of finished products for research supply.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Fundamentals of Psychedelic-Assisted Therapy — approximately 50 hours over 8 weeks with 2.5-hour pre-work modules and 3-hour live interactive sessions plus small group learning |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Numinus Wellness product offering
Product offeringCore offering
Numinus Wellness operates an integrated mental health company delivering psychedelic-assisted therapy clinical services through owned clinics in Canada (Vancouver, Montreal, Toronto), board-accredited practitioner training programs for psychedelic therapy certification, and clinical trial site operations (Cedar Clinical Research) supporting psychedelic medicine research. Supporting infrastructure includes Numinus Bioscience, a Health Canada licensed laboratory for psychedelic compound production and extraction covering psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine.
Product overview
Numinus Wellness operates as an integrated mental health company offering a platform of clinical services, provider training, and clinical research. The core offerings include Provider Training (accredited psychedelic-assisted therapy certification programs), Clinical Trials (through Cedar Clinical Research), and direct patient treatment services (ketamine, psilocybin, and MDMA-assisted therapy). Supporting infrastructure includes Numinus Bioscience (research laboratory), the Numinus Care Model (trauma-informed care framework), and the Numinus Alumni Network (graduate support community). The company also operates clinics across Canada and acquired the Neurology Centre of Toronto to expand into psychedelic neurology services.
Differentiator
Problem solved
Functional benefit
Brands
- Numinus Health: Clinic operations and patient care division providing psychedelic-assisted therapies
- Numinus Bioscience
- Numinus Training
- Neurology Centre of Toronto by Numinus
Products and services
- Provider Training Board-accredited Psychedelic-Assisted Therapy certification programs and stand-alone courses for licensed mental health professionals and non-licensed practitioners, covering ketamine, psilocybin, and MDMA-assisted therapy. Over 2,500 practitioners trained to date.
- Clinical Trials Clinical research site services through Cedar Clinical Research, conducting psychedelic-assisted therapy trials, compassionate access programs, and Phase 1 studies for pharmaceutical and research clients.
- Ketamine-Assisted Therapy Clinical treatment using ketamine for depression, anxiety, PTSD, and other mental health conditions, including Spravato (esketamine) treatments, delivered in owned Canadian clinics.
- Psilocybin-Assisted Therapy Treatment using psilocybin for treatment-resistant depression, PTSD, anxiety, and substance use disorders through clinical trials and Health Canada Special Access Program.
- MDMA-Assisted Therapy Treatment using MDMA for PTSD delivered through MAPS-sponsored clinical trials and compassionate access programs.
- Numinus Bioscience Health Canada licensed laboratory conducting psychedelic research, extraction, and production including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine for clinical trials and research supply.
- Transcranial Magnetic Stimulation (TMS) Non-invasive brain stimulation therapy offered at Neurology Centre of Toronto by Numinus alongside psychedelic-assisted therapies.
Quantifiable outcome
- Revenue increased 160% year-over-year for Q3 2021 vs. Q3 2020 (Q3 2021: $562,076 vs. Q3 2020: $216,244)
- +3 more outcomes
Companies that use Numinus Wellness
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Numinus Wellness technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Numinus Wellness partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- StellaminorAs part of the US$3.53 million sale of five Utah clinics, Numinus entered into a data partnership with Stella for data sharing to develop clinic management solutions. Stella enhances operational efficiency across its clinic network through this arrangement.
- MedBright AIcoreNuminus announced strategic acquisition of MedBright AI, with plans to rebrand as Numinus Intelligence to leverage AI in mental health clinics across the U.S. The transaction involves issuing approximately 204.7 million Numinus shares. The acquisition aims to enhance mental health treatment offerings through AI-enabled solutions and generate revenue and profitability.
- MAPS (Multidisciplinary Association for Psychedelic Studies)coreHealth Canada approved the compassionate access trial of MDMA-assisted therapy for PTSD and concurrent disorders in collaboration with MAPS. This partnership enables real-world data collection on a regulated model for MDMA-assisted therapy, leveraging Numinus' clinical trial site infrastructure.
- Dr. Gabor Maté (Clinical Advisory Council)minorDr. Gabor Maté, a recognized physician and bestselling author, joined Numinus as a member of the Clinical Advisory Council. He collaborates with the Numinus team in an advisory capacity and facilitates connections within the mental health community.
- Health CanadacoreHealth Canada has granted Numinus Bioscience licenses enabling research, extraction, and production of controlled substances including psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine. Through the Special Access Program (SAP), physicians can request access to psilocybin and MDMA for patients with treatment-resistant conditions.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Numinus Wellness competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Numinus Wellness social profiles
Digital presenceNuminus Wellness financial estimates
Financial estimateRevenue estimate
Valuation estimate
Numinus Wellness leadership team
Management profileNumber of profiles
Profiles13 records
Numinus Wellness subsidiaries and ownership
Company hierarchySubsidiaries4 records
Numinus Wellness funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Numinus Wellness M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Numinus Wellness
What does Numinus Wellness do?
Numinus Wellness operates an integrated mental health company delivering psychedelic-assisted therapy clinical services through owned clinics in Canada (Vancouver, Montreal, Toronto), board-accredited practitioner training programs for psychedelic therapy certification, and clinical trial site operations (Cedar Clinical Research) supporting psychedelic medicine research. Supporting infrastructure includes Numinus Bioscience, a Health Canada licensed laboratory for psychedelic compound production and extraction covering psilocybin, DMT, MDMA, mescaline, psilocin, LSD, and ketamine.
Is Numinus Wellness a public or private company?
Numinus Wellness is a public company. It is classified as public and is currently operating.
When was Numinus Wellness founded?
Numinus Wellness was founded in 2020. It employs 251 to 500 people.
Where is Numinus Wellness based?
Numinus Wellness is headquartered in Salt Lake City, United States, in the North America region.
How does Numinus Wellness make money?
Three revenue lines are on record. Clinical Services Revenue is the primary driver. The others are practitioner Training Programs and laboratory & Research Services.
Does Numinus Wellness have an API?
No public API is recorded for Numinus Wellness.
What industry is Numinus Wellness in?
Numinus Wellness's product category is Mental Health Services. Its primary akta.pro industry code is HLALAEAA, General Mental Health Therapy Platforms (Talk Therapy), with a secondary code of HSADAJAH, Meditation Apps, Digital Courses & Online Communities. Its NAICS code is 621420 and its SIC code is 8000.